<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319711409391</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319711409391</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Risk Factors</subject>
</subj-group>
</article-categories>
<title-group><article-title>The Influence of Risk Factors for Metabolic Syndrome on Vascular Complications</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Irzmański</surname>
<given-names>Robert</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0003319711409391">1</xref>
<xref ref-type="aff" rid="aff2-0003319711409391">2</xref>
<xref ref-type="corresp" rid="corresp1-0003319711409391"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Śliwczyńska-Rodziewicz</surname>
<given-names>Dorota</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-0003319711409391">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pawlicki</surname>
<given-names>Lucjan</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0003319711409391">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kowalski</surname>
<given-names>Jan</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-0003319711409391">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319711409391"><label>1</label>Medical University of Łódź, Clinic of Internal Diseases and Cardiological Rehabilitation, Łódź, Poland</aff>
<aff id="aff2-0003319711409391"><label>2</label>Medical University of Łódź, Laboratory of Ergonomics and Exercise Physiology, Łódź, Poland</aff>
<aff id="aff3-0003319711409391"><label>3</label>Department of Ophthalmology, County Hospital in Zgierz, Zgierz, Poland</aff>
<author-notes>
<corresp id="corresp1-0003319711409391">Robert Irzmański, Medical University of Łódź, Hallera 1, 90-647 Łódź, Poland Email:<email>robert.irzmanski@umed.lodz.pl</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>63</volume>
<issue>2</issue>
<fpage>86</fpage>
<lpage>91</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder></permissions>
<abstract>
<p>We assessed the influence of metabolic syndrome (MetS) characteristics on vascular complications. The study included 108 patients (72 women and 36 men, age 57.0 ± 8.5 years) with MetS that was diagnosed according to International Diabetes Federation criteria. The prevalence of micro- and macrovascular complications was assessed: vascular changes in the fundus of the eye—72%, ischemic heart disease—54.9%, estimated glomerular filtration rate (eGFR) &lt;90 mL/min—38.9%, diabetic foot—5.55%, and cerebrovascular accident—3.7% of patients. A negative correlation between high-density lipoprotein cholesterol (HDL-C) concentration, creatinine levels, and level of vascular changes in the fundus of the eye was found. Moreover, the level of obesity and fasting glucose level had positive correlation with the intensity of vascular changes in the fundus of the eye. Characteristics of MetS (obesity and fasting glucose level) have high impact on advancing vascular complications in these patients. High level of HDL-C decreases the intensity of vascular changes in patients with MetS.</p>
</abstract>
<kwd-group>
<kwd>metabolic syndrome</kwd>
<kwd>vascular complication</kwd>
<kwd>risk factors</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319711409391">
<title>Introduction</title>
<p>Metabolic syndrome (MetS) is a combination of characteristics that include central obesity, dyslipidemia, insulin resistance, and hypertension.<sup><xref ref-type="bibr" rid="bibr1-0003319711409391">1</xref>,<xref ref-type="bibr" rid="bibr2-0003319711409391">2</xref></sup> These factors cause endothelial inflammation and atherogenesis and are connected with an increased risk of cardiovascular events and development of type 2 diabetes mellitus (T2DM).<sup><xref ref-type="bibr" rid="bibr3-0003319711409391">3</xref><xref ref-type="bibr" rid="bibr4-0003319711409391"/><xref ref-type="bibr" rid="bibr5-0003319711409391"/>–<xref ref-type="bibr" rid="bibr6-0003319711409391">6</xref></sup>
</p>
<p>Adipose tissue affects the intensity of inflammation by producing adipocytokines which, in turn, lead to further activation of endothelial inflammatory response.<sup><xref ref-type="bibr" rid="bibr7-0003319711409391">7</xref></sup> There is a connection between levels of acute-phase proteins such as C-reactive protein (CRP) and fibrinogen and the inflammatory response of the endothelium.<sup><xref ref-type="bibr" rid="bibr8-0003319711409391">8</xref></sup> Furthermore, increased production of uric acid may lead to increased synthesis of oxygen-free radicals that impair the endothelial function by decreased synthesis of nitric oxide (NO).<sup><xref ref-type="bibr" rid="bibr9-0003319711409391">9</xref></sup>
</p>
<p>Damage of the endothelium due to inflammation is an important link in the pathogenesis of arterial hypertension and atherosclerosis, which leads to ischemic heart disease (IHD).</p>
</sec>
<sec id="section2-0003319711409391">
<title>Materials and Methods</title>
<p>We studied 108 people (72 women and 36 men, aged 46-67 years, average age 57.0 ± 8.5 years) with MetS, which was diagnosed according to International Diabetes Federation (IDF) criteria 2005<sup><xref ref-type="bibr" rid="bibr10-0003319711409391">10</xref></sup>, with the following criteria:<list list-type="bullet">
<list-item>
<p>abdominal obesity;</p>
</list-item>
<list-item>
<p>triglycerides (TG) ≥150 mg/dL or on TG-lowering treatment;</p>
</list-item>
<list-item>
<p>high-density lipoprotein cholesterol (HDL-C) &lt;40 mg/dL in men or &lt;50 mg/dL in women, or treatment for low HDL-C;</p>
</list-item>
<list-item>
<p>blood pressure ≥130/≥85 mm Hg or on antihypertensive medication;</p>
</list-item>
<list-item>
<p>glucose: ≥100 mg/dL or on treatment of DM.</p>
</list-item>
</list>All the study participants were volunteers and signed an informed consent form before their inclusion in the study, and the study was approved by the local Ethics Committee of the Medical University in Lodz. The Helsinki declaration recommendations were observed.</p>
<sec id="section3-0003319711409391">
<title>General Description of Study Group With MetS</title>
<p>Diagnosis of IHD was based on the coronary angiography and/or medical documentation (<xref ref-type="table" rid="table1-0003319711409391">Table 1</xref>
).</p>
<table-wrap id="table1-0003319711409391" position="float">
<label>Table 1.</label>
<caption>
<p>General Description of Study Group With MetS</p>
</caption>
<graphic alternate-form-of="table1-0003319711409391" xlink:href="10.1177_0003319711409391-table1.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Average</th>
<th>Median</th>
<th>Minimum</th>
<th>Maximum</th>
<th>Q25</th>
<th>Q75</th>
<th>Standard Deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>60.1</td>
<td>60.5</td>
<td>46.0</td>
<td>74.0</td>
<td>56.0</td>
<td>65.0</td>
<td>6.6</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>90.9</td>
<td>90.5</td>
<td>62.0</td>
<td>130.0</td>
<td>77.5</td>
<td>103.0</td>
<td>18.0</td>
</tr>
<tr>
<td>Waist (cm)</td>
<td>114.8</td>
<td>116.0</td>
<td>93.0</td>
<td>145.0</td>
<td>104.5</td>
<td>122.5</td>
<td>13.0</td>
</tr>
<tr>
<td>SBP (mm Hg)</td>
<td>153.7</td>
<td>150.0</td>
<td>110.0</td>
<td>270.0</td>
<td>140.0</td>
<td>170.0</td>
<td>25.4</td>
</tr>
<tr>
<td>DBP (mm Hg)</td>
<td>91.0</td>
<td>90.0</td>
<td>60.0</td>
<td>120.0</td>
<td>85.0</td>
<td>100.0</td>
<td>12.5</td>
</tr>
<tr>
<td>Glucose (mg/dL)</td>
<td>143</td>
<td>132</td>
<td>81</td>
<td>313</td>
<td>106</td>
<td>162</td>
<td>49</td>
</tr>
<tr>
<td>Cholesterol (mg/dL)</td>
<td>212</td>
<td>209</td>
<td>142</td>
<td>334</td>
<td>173</td>
<td>234</td>
<td>47</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>153</td>
<td>152</td>
<td>60</td>
<td>291</td>
<td>107</td>
<td>190</td>
<td>56</td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>54</td>
<td>50</td>
<td>34</td>
<td>93</td>
<td>45</td>
<td>60</td>
<td>13</td>
</tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>128</td>
<td>121</td>
<td>48</td>
<td>258</td>
<td>94</td>
<td>154</td>
<td>44</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319711409391">
<p>Abbreviations: MetS, metabolic syndrome; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. Q25, quartile I; Q75, quartile III</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Kidney function was assessed by estimated glomerular filtration rate (eGFR) calculated using the modification of diet in renal disease (MDRD) formula: eGFR=186.3×serum creatinine<sup>−1.154</sup>×age<sup>−0.203</sup>×0.742 (for female), where Cr is the serum creatinine level.<sup><xref ref-type="bibr" rid="bibr11-0003319711409391">11</xref></sup>
</p>
<p>Vascular changes in the fundus of the eye (angiopathy and/or retinopathy) were assessed in ophthalmoscopy and flourescence angiography. The level of retinopathy development was assessed according to World Health Organization (WHO) classification for diabetic retinopathy<sup><xref ref-type="bibr" rid="bibr12-0003319711409391">12</xref></sup>:<list list-type="bullet">
<list-item>
<p>nonproliferative diabetic retinopathy without maculopathy;</p>
</list-item>
<list-item>
<p>nonproliferative diabetic retinopathy with maculopathy;</p>
</list-item>
<list-item>
<p>preproliferative diabetic retinopathy;</p>
</list-item>
<list-item>
<p>proliferative diabetic retinopathy without complications;</p>
</list-item>
<list-item>
<p>proliferative diabetic retinopathy with complications.</p>
</list-item>
</list>For statistical analysis, the results of examination of the fundus of the eye were coded with a scale of 0 to 6, where 0 = <italic>lack of vascular changes</italic>, 1 = <italic>angiopathy</italic>, and 2 to 6 = <italic>next levels of retinopathy</italic>.</p>
<p>The interviews and medical documentation analysis were performed to establish prior cerebrovascular accident and diabetic foot occurrence.</p>
<p>Blood samples were collected from an antecubital vein in the early morning, 12 hours after the previous meal. All the assays were performed within 2 hours of blood collection. The laboratory staff that performed the assays was blind to the group the sample came from.</p>
</sec>
<sec id="section4-0003319711409391">
<title>Statistical Analysis</title>
<p>Standard deviation and average values are reported. To assess the dependence between achieved variables, we used:<list list-type="bullet">
<list-item>
<p>Spearman rank correlation coefficient for comparison of 2 values;</p>
</list-item>
<list-item>
<p>chi-square test for comparison of frequencies.</p>
</list-item>
</list>A <italic>P</italic> value &lt;.05 was considered significant.</p>
</sec>
</sec>
<sec id="section5-0003319711409391">
<title>Results</title>
<p>Characteristics of the study population were included in<xref ref-type="table" rid="table1-0003319711409391">Table 1</xref>. In all, 60% of patients were declared nicotinism. The prevalence of vascular complications in patients with MetS is described in<xref ref-type="fig" rid="fig1-0003319711409391">Figure 1</xref>
. Average fasting glucose level in the plasma of patients with MetS and IHD was 156 ± 54 mg/dL and was on average 32 mg/dL higher compared to the fasting glucose level in patients without IHD (124 ± 33 mg/dL; <italic>P</italic> &lt; .05). In patients with MetS and IHD, the mean blood pressure, HDL-C, low-density lipoprotein cholesterol (LDL-C), and TG values as well as waist circumference and body mass were not significantly different compared with those in patients with MetS but without IHD.</p>
<fig id="fig1-0003319711409391" position="float">
<label>Figure 1.</label>
<caption>
<p>The prevalence of vascular complications in patients with metabolic syndrome. IHD indicates ischemic heart disease; GFR, glomerular filtration rate.</p>
</caption>
<graphic xlink:href="10.1177_0003319711409391-fig1.tif"/>
</fig>
<p>There was no correlation between fasting glucose level and eGFR; nevertheless, 84.21% patients with MetS and eGFR &lt;90 mL/min had T2DM.</p>
<p>There was no correlation between blood pressure and eGFR; all patients with eGFR &lt;90 mL/min had hypertension.</p>
<p>Negative correlation <italic>P</italic> &lt; .01, was found between serum HDL-C and Cr levels (<xref ref-type="fig" rid="fig2-0003319711409391">Figure 2</xref>
).</p>
<fig id="fig2-0003319711409391" position="float">
<label>Figure 2.</label>
<caption>
<p>Correlation between the level of high-density lipoprotein cholesterol (HDL-C) and serum creatinine.</p>
</caption>
<graphic xlink:href="10.1177_0003319711409391-fig2.tif"/>
</fig>
<p>There was a positive correlation between obesity and the level of vascular abnormalities in the fundus of the eye (<xref ref-type="fig" rid="fig3-0003319711409391">Figures 3</xref> and<xref ref-type="fig" rid="fig4-0003319711409391">4</xref>) and between glucose level and the level of vascular abnormalities development in the fundus (<xref ref-type="fig" rid="fig5-0003319711409391">Figure 5</xref>). Patients with higher glucose levels had more complicated vascular abnormalities in the fundus. We also found a negative correlation between HDL-C level and vascular abnormalities in the fundus (<xref ref-type="fig" rid="fig6-0003319711409391">Figure 6</xref>). We did not note any correlation between blood pressure and vascular abnormalities in the fundus of the eye.</p>
<fig id="fig3-0003319711409391" position="float">
<label>Figure 3.</label>
<caption>
<p>Correlation between weight and the level of vascular abnormalities development in the fundus of the eye.</p>
</caption>
<graphic xlink:href="10.1177_0003319711409391-fig3.tif"/>
</fig>
<fig id="fig4-0003319711409391" position="float">
<label>Figure 4.</label>
<caption>
<p>Correlation between waist and the level of vascular abnormalities development in the fundus of the eye.</p>
</caption>
<graphic xlink:href="10.1177_0003319711409391-fig4.tif"/>
</fig>
<fig id="fig5-0003319711409391" position="float">
<label>Figure 5.</label>
<caption>
<p>Correlation between glucose level and the level of vascular abnormalities development in the fundus of the eye.</p>
</caption>
<graphic xlink:href="10.1177_0003319711409391-fig5.tif"/>
</fig>
<fig id="fig6-0003319711409391" position="float">
<label>Figure 6.</label>
<caption>
<p>Correlation between high-density lipoprotein cholesterol (HDL-C) level and vascular abnormalities in the fundus of the eye.</p>
</caption>
<graphic xlink:href="10.1177_0003319711409391-fig6.tif"/>
</fig>
</sec>
<sec id="section6-0003319711409391">
<title>Discussion</title>
<p>We assessed the correlation between the characteristics of MetS and vascular complications. We observed vascular abnormalities in the fundus of the eye (72.7%). Angiopathy was observed in 41.2% and retinopathy in 31.5% of patients with MetS. Ischemic heart disease was diagnosed in 54.9% of patients, and lowered eGFR &lt;90 mL/min, was reported in 38.9% of patients with MetS. Other vascular complications were less frequent.</p>
<p>Fasting glucose level in patients with MetS and IHD was significantly higher than in those without IHD. Moreover, MetS with coexisting IHD was more frequent in patients with T2DM (61.4% vs 14.3%).</p>
<p>The Framingham Offspring Study showed that the influence of MetS on T2DM development is stronger than that on cardiovascular disorders.<sup><xref ref-type="bibr" rid="bibr13-0003319711409391">13</xref></sup> Some researchers suggest that impaired glucose tolerance, and even more T2DM, have stronger influence on development of cardiovascular disorders than all other diagnostic characteristics for MetS. For example, Malik and associates assessed total death risk and death risk because of IHD and other cardiovascular disorders and reported that it is much higher for people with T2DM than those with MetS (respectively, 2.1, 5.0, and 3.6 vs 1.5, 2.5, and 3.7).<sup><xref ref-type="bibr" rid="bibr14-0003319711409391">14</xref></sup> Stern etal also proved that patients with IHD and coexisting MetS had higher death risk, but glycemic control significantly decreases this risk.<sup><xref ref-type="bibr" rid="bibr15-0003319711409391">15</xref></sup> In contrast, several studies do not confirm these conclusions. Alexander’s study<sup><xref ref-type="bibr" rid="bibr16-0003319711409391">16</xref></sup> showed that MetS is as important as DM in the development of IHD. In the US population, patients with MetS and undiagnosed T2DM are more vulnerable to the development of IHD than patients with T2DM but without other metabolic disorders (13.9% vs 7.5%).</p>
<p>Diabetes mellitus is the most important cause of microangiopathy.<sup><xref ref-type="bibr" rid="bibr17-0003319711409391">17</xref></sup> Tight correlation between insulin resistance, T2DM, and MetS causes patients with MetS to have a high risk of developing microvascular complications.<sup><xref ref-type="bibr" rid="bibr18-0003319711409391">18</xref></sup> Hyperglycemia has a high impact on carbohydrate metabolism that leads to abnormalities in the microcirculation and organ damage.<sup><xref ref-type="bibr" rid="bibr19-0003319711409391">19</xref></sup> The role of DM in retinopathy and nephropathy was proven in many studies.<sup><xref ref-type="bibr" rid="bibr20-0003319711409391">20</xref></sup> Also, in our study high glucose level and the presence of T2DM were highly correlated with vascular abnormalities in the retina. The glucose level is positively correlated with the retinopathy development in patients with MetS.</p>
<p>Although hyperglycemia is a factor causing microangiopathy, it is not the only risk factor in patients with MetS. Other metabolic disorders that are part of MetS may have important influence on developing microangiopathy. In 700 participants in the Diabetes Control and Complication Trial (DCCT) study, it was noted that an atherogenic lipid profile including increased level of TG, total cholesterol, and LDL-C correlates with increased risk of nephropathy (defined as microalbuminuria). There was no correlation observed between serum HDL-C level and microalbuminuria.<sup><xref ref-type="bibr" rid="bibr21-0003319711409391">21</xref></sup> Agrawal and associates reported other results while observing over 4000 patients with DM. They noted a correlation between nephropathy and increased LDL-C levels as well as lowered HDL-C level.<sup><xref ref-type="bibr" rid="bibr22-0003319711409391">22</xref></sup> Studies of other authors confirm this observation.<sup><xref ref-type="bibr" rid="bibr23-0003319711409391">23</xref>,<xref ref-type="bibr" rid="bibr24-0003319711409391">24</xref></sup>
</p>
<p>Mänttäri and associates<sup><xref ref-type="bibr" rid="bibr25-0003319711409391">25</xref></sup> also reported the influence of inappropriate HDL-C level on the development of nephropathy. They assessed changes in Cr levels in 2702 men with dyslipidemia during 5 years of observation in the Helsinki Heart Study. In patients who had an LDL-C-to-HDL-C ratio of more than 4.4, the nephrons lost their function 20% quicker than in patients with the ratio less than 3.2. Furthermore, this study proved that HDL-C has a nephroprotective function. The results did not show any correlation between serum Cr and TG levels.</p>
<p>The ARICS (Atherosclerosis Risk in Communities Study) study showed that low HDL-C level was an important, independent risk factor for lowered GFR.<sup><xref ref-type="bibr" rid="bibr26-0003319711409391">26</xref></sup> Also, other studies showed that a low HDL-C level as well as an increased TG level is an independent risk factor leading to impaired renal function and renal failure.<sup><xref ref-type="bibr" rid="bibr27-0003319711409391">27</xref></sup> The Hoorn Study showed that increased total cholesterol level and TG have positive correlation with developing retinopathy and presence of hard effusions in the retina.<sup><xref ref-type="bibr" rid="bibr18-0003319711409391">18</xref></sup>
</p>
<p>Several studies concerning lipid-lowering drugs showed an influence of lipid disorders on the development of microvascular complications. These drugs have a positive effect on the vascular complications in kidneys and retina. The Heart Protection Study<sup><xref ref-type="bibr" rid="bibr28-0003319711409391">28</xref></sup> showed that people taking 40 mg of simvastatin had a lowered risk of decreasing GFR by 25%. A beneficial effect of statins on renal function and vascular events in patients with IHD and MetS was reported.<sup><xref ref-type="bibr" rid="bibr29-0003319711409391">29</xref></sup> The FIELD study during 5 years observation showed that the study population taking fenofibrate had a lowered risk of microvascular complications. In patients taking fenofibrate the risk of nephropathy progression and retina laserotherapy was lower in comparison to those taking placebo (3.6% vs 5.2%). In the fenofibrate group compared with placebo, there was a significant reduction in the need to perform laser treatment due to the slow progression of retinopathy and albuminuria. The use of fenofibrate decreased the risk of coronary events, strokes, cardiovascular mortality, and needs of coronary revascularization of the cervical vessels by 19%. The use of fenofibrate was associated with a significant reduction in non-complete heart attacks and the need for coronary revascularization.<sup><xref ref-type="bibr" rid="bibr30-0003319711409391">30</xref></sup>
</p>
<p>Our results show that HDL-C has a protective influence on microvessels, in accordance with Agrawal’s results.<sup><xref ref-type="bibr" rid="bibr22-0003319711409391">22</xref></sup> Higher levels of HDL-C in patients with MetS were positively correlated with less advanced vascular changes in retina and lower Cr level, although this was not significant for GFR. In patients with MetS, we did not observe any relationship between the level of total cholesterol or TG and advancement of retinopathy. According to the literature, the levels of these lipids mainly affect the presence of hard effusions in retina.<sup><xref ref-type="bibr" rid="bibr18-0003319711409391">18</xref></sup> We did not statistically analyze the presence of these effusions; it was only one of the features of retinopathy.</p>
<p>It seems that obesity plays an important role in developing microvascular complications in patients with MetS.<sup><xref ref-type="bibr" rid="bibr30-0003319711409391">30</xref><xref ref-type="bibr" rid="bibr31-0003319711409391"/>–<xref ref-type="bibr" rid="bibr32-0003319711409391">32</xref></sup> Obesity favors insulin resistance and metabolic disorders leading to microangiopathy. De Block’s studies in patients with type 1 DM showed that obesity favors developing retinopathy and neuropathy and that the body mass index (BMI) in patients with these complications is higher.<sup><xref ref-type="bibr" rid="bibr33-0003319711409391">33</xref></sup> Katusic and associates reported similar results by assessing the prevalence of retinopathy in patients with T2DM. The results are in accordance with van Leiden’s earlier observations.<sup><xref ref-type="bibr" rid="bibr18-0003319711409391">18</xref></sup>
</p>
<p>Similar conclusions appear in the literature concerning nephropathy. In the UKPDS, obesity defined by increased waist circumference was an independent risk factor for microalbuminuria.<sup><xref ref-type="bibr" rid="bibr34-0003319711409391">34</xref></sup> In another study, a BMI &gt;28.6 kg/m<sup>2</sup> increased the risk of proteinuria.<sup><xref ref-type="bibr" rid="bibr35-0003319711409391">35</xref></sup> The above-mentioned reports concerned patients with T2DM. Pataap and associates reported that central obesity may be an early and independent risk factor for albuminuria also in patients with normal level of serum glucose.<sup><xref ref-type="bibr" rid="bibr32-0003319711409391">32</xref></sup> The results of our study also point out the existence of a relationship between obesity, waist circumference, and microangiopathy.</p>
<p>Our results suggest that MetS risk factors significantly affect the intensity of vascular complications. We also showed that higher serum HDL-C levels decrease the intensity of vascular changes in patients with MetS.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319711409391">
<p>The author(s) declared no conflicts of interest with respect to the authorship and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0003319711409391">
<p>The author(s) received no financial support for the research and/or authorship of this article</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319711409391">
<label>1</label>
<citation citation-type="journal">
<collab collab-type="author">Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults</collab>. <article-title>Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)</article-title>. <source>JAMA</source>. <year>2001</year>;<volume>285</volume>(<issue>19</issue>):<fpage>2486</fpage>–<lpage>2497</lpage>.</citation>
</ref>
<ref id="bibr2-0003319711409391">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ford</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Giles</surname>
<given-names>WH.</given-names>
</name>
</person-group> <article-title>A comparison of the prevalence of the metabolic syndrome using two proposed definitions</article-title>. <source>Diabetes Care</source>. <year>2003</year>;<volume>26</volume>(<issue>3</issue>):<fpage>575</fpage>–<lpage>581</lpage>.</citation>
</ref>
<ref id="bibr3-0003319711409391">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pearson</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Blair</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Daniels</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Eckel</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Fair</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Fortmann</surname>
<given-names>SP.</given-names>
</name>
</person-group> <article-title>AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>106</volume>(<issue>3</issue>):<fpage>388</fpage>–<lpage>391</lpage>.</citation>
</ref>
<ref id="bibr4-0003319711409391">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grundy</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Cleeman</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Kann</surname>
<given-names>RA.</given-names>
</name>
</person-group> <article-title>American Heart Association: National Heart, Lung, and Blood Institute: American Diabetes Association. Clinical management of metabolic syndrome report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>109</volume>(<issue>4</issue>):<fpage>551</fpage>–<lpage>556</lpage>.</citation>
</ref>
<ref id="bibr5-0003319711409391">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Isomaa</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Almgren</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Tuomi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Forsen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lahti</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nissen</surname>
<given-names>M.</given-names>
</name>
</person-group> <article-title>Cardiovascular morbidity and mortality associated with the metabolic syndrome</article-title>. <source>Diabetes Care</source>. <year>2001</year>;<volume>24</volume>(<issue>4</issue>):<fpage>683</fpage>–<lpage>689</lpage>.</citation>
</ref>
<ref id="bibr6-0003319711409391">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lakka</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Laaksonen</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Lakka</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Niskanen</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Kumpusalo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tuomilehto</surname>
<given-names>J.</given-names>
</name>
</person-group> <article-title>The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men</article-title>. <source>JAMA</source>. <year>2002</year>;<volume>288</volume>(<issue>21</issue>):<fpage>2709</fpage>–<lpage>2716</lpage>.</citation>
</ref>
<ref id="bibr7-0003319711409391">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasceri</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Willerson</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>T.</given-names>
</name>
</person-group> <article-title>Direct proinflammatory effect of C-reactive protein on human endothelial cells</article-title>. <source>Circulation</source>. <year>2000</year>;<volume>102</volume>(<issue>18</issue>):<fpage>2165</fpage>–<lpage>2168</lpage>.</citation>
</ref>
<ref id="bibr8-0003319711409391">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yarnell</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Sweetnam</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Rumley</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lowe</surname>
<given-names>GD.</given-names>
</name>
</person-group> <article-title>Lifestyle and hemostatic risk factors for ischemic heart disease. The Caerphilly Study</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2000</year>;<volume>20</volume>(<issue>1</issue>):<fpage>271</fpage>–<lpage>279</lpage>.</citation>
</ref>
<ref id="bibr9-0003319711409391">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doehner</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Schoene</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Rauchhaus</surname>
<given-names>M</given-names>
</name>
<name>
<surname>LeyvaLeon</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pavitt</surname>
<given-names>DV</given-names>
</name>
<name>
<surname>Reaveley</surname>
<given-names>DA.</given-names>
</name>
</person-group> <article-title>Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>105</volume>(<issue>22</issue>):<fpage>2619</fpage>–<lpage>2624</lpage>.</citation>
</ref>
<ref id="bibr10-0003319711409391">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saely</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Koch</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography</article-title>. <source>Diabetes Care</source>. <year>2006</year>;<volume>29</volume>(<issue>4</issue>):<fpage>901</fpage>–<lpage>907</lpage>.</citation>
</ref>
<ref id="bibr11-0003319711409391">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poggio</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Van Lente</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>PM.</given-names>
</name>
</person-group> <article-title>Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease</article-title>. <source>J Am Soc Nephrol</source>. <year>2005</year>;<volume>16</volume>(<issue>2</issue>):<fpage>459</fpage>–<lpage>466</lpage>.</citation>
</ref>
<ref id="bibr12-0003319711409391">
<label>12</label>
<citation citation-type="journal">
<collab collab-type="author">World Health Organization: Definition diagnosis and classification of diabetes mellitus and its complications</collab>. <article-title>Report of a WHO consultation. Part 1. Dizgnosis and classification of diabetes mellitus. WHO, Genewa 1999</article-title>. <source>Med Prakt</source>. <year>2000</year>;<volume>1-2</volume>:<fpage>85</fpage>–<lpage>109</lpage>.</citation>
</ref>
<ref id="bibr13-0003319711409391">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peter</surname>
<given-names>WFW</given-names>
</name>
<name>
<surname>James</surname>
<given-names>BM.</given-names>
</name>
</person-group> <article-title>Risk of type 2 diabetes mellitus and coronary heart disease: a pivotal role for metabolic factors</article-title>. <source>Eur Heart J Suppl</source>. <year>2008</year>;<volume>10</volume>(<issue>2</issue>):<fpage>11</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr14-0003319711409391">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malik</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Franklin</surname>
<given-names>SS</given-names>
</name>
<etal/>
</person-group>. <article-title>Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease and on all causes in United States adults</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>110</volume>(<issue>10</issue>):<fpage>1245</fpage>–<lpage>1250</lpage>.</citation>
</ref>
<ref id="bibr15-0003319711409391">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stern</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>K</given-names>
</name>
<name>
<surname>González-Villalpando</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hunt</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Haffner</surname>
<given-names>SM.</given-names>
</name>
</person-group> <article-title>Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?</article-title> <source>Diabetes Care</source>. <year>2004</year>;<volume>27</volume>(<issue>11</issue>):<fpage>2676</fpage>–<lpage>2681</lpage>.</citation>
</ref>
<ref id="bibr16-0003319711409391">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alexander</surname>
<given-names>CM.</given-names>
</name>
</person-group> <article-title>NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older</article-title>. <source>Diabetes</source>. <year>2003</year>;<volume>52</volume>(<issue>5</issue>):<fpage>1210</fpage>–<lpage>1214</lpage>.</citation>
</ref>
<ref id="bibr17-0003319711409391">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>TY.</given-names>
</name>
</person-group> <article-title>Retinal vascular manifestations of metabolic disorders</article-title>. <source>Trends Endocrinol Metab</source>. <year>2006</year>;<volume>17</volume>(<issue>7</issue>):<fpage>262</fpage>–<lpage>268</lpage>.</citation>
</ref>
<ref id="bibr18-0003319711409391">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Leiden</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Dekker</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Moll</surname>
<given-names>AC</given-names>
</name>
<etal/>
</person-group>. <article-title>Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn study</article-title>. <source>Diabetes Care</source>. <year>2002</year>;<volume>25</volume>(<issue>8</issue>):<fpage>1320</fpage>–<lpage>1325</lpage>.</citation>
</ref>
<ref id="bibr19-0003319711409391">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schrier</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Estacio</surname>
<given-names>RO</given-names>
</name>
<name>
<surname>Esler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mehler</surname>
<given-names>P.</given-names>
</name>
</person-group> <article-title>Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes</article-title>. <source>Kidney Int</source>. <year>2002</year>;<volume>61</volume>(<issue>3</issue>):<fpage>1086</fpage>–<lpage>1097</lpage>.</citation>
</ref>
<ref id="bibr20-0003319711409391">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cardoso</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Salles</surname>
<given-names>GF.</given-names>
</name>
</person-group> <article-title>Predictors of development and progression of microvascular complications in a cohort of Brazilian type 2 diabetic patients</article-title>. <source>J Diabetes Complications</source>. <year>2008</year>;<volume>22</volume>(<issue>3</issue>):<fpage>164</fpage>–<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr21-0003319711409391">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jenkins</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Lyons</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy</article-title>. <source>Kidney Int</source>. <year>2003</year>;<volume>64</volume>(<issue>3</issue>):<fpage>817</fpage>–<lpage>828</lpage>.</citation>
</ref>
<ref id="bibr22-0003319711409391">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agrawal</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pal</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kochar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kochar</surname>
<given-names>DK.</given-names>
</name>
</person-group> <article-title>Magnitude of dyslipidemia and its association with micro and macrovascular complications in type 2 diabetes: a hospital based study from Bikaner (Northwest India)</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2006</year>;<volume>73</volume>(<issue>2</issue>):<fpage>211</fpage>–<lpage>214</lpage>.</citation>
</ref>
<ref id="bibr23-0003319711409391">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Athyros</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Papageorgiou</surname>
<given-names>AA</given-names>
</name>
<etal/>
</person-group>. <article-title>The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study</article-title>. <source>J Clin Pathol</source>. <year>2004</year>;<volume>57</volume>(<issue>7</issue>):<fpage>728</fpage>–<lpage>734</lpage>.</citation>
</ref>
<ref id="bibr24-0003319711409391">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Athyros</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Elisaf</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Papageorgiou</surname>
<given-names>AA</given-names>
</name>
<etal/>
</person-group>. <article-title>and the GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study</article-title>. <source>Am J Kidney Dis</source>. <year>2004</year>;<volume>43</volume>(<issue>4</issue>):<fpage>589</fpage>–<lpage>599</lpage>.</citation>
</ref>
<ref id="bibr25-0003319711409391">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mänttäri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tiula</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Alikoski</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Manninen</surname>
<given-names>V.</given-names>
</name>
</person-group> <article-title>Effects of hypertension and dyslipidemia on the decline in renal function</article-title>. <source>Hypertension</source>. <year>1995</year>;<volume>26</volume>(<issue>4</issue>):<fpage>670</fpage>–<lpage>675</lpage>.</citation>
</ref>
<ref id="bibr26-0003319711409391">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muntner</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Coresh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Eckfeldt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Klag</surname>
<given-names>MJ.</given-names>
</name>
</person-group> <article-title>Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study</article-title>. <source>Kidney Int</source>. <year>2000</year>;<volume>58</volume>(<issue>1</issue>):<fpage>293</fpage>–<lpage>301</lpage>.</citation>
</ref>
<ref id="bibr27-0003319711409391">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fried</surname>
<given-names>LF</given-names>
</name>
<name>
<surname>Orchard</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Kasiske</surname>
<given-names>BL.</given-names>
</name>
</person-group> <article-title>Effect of lipid reduction on the progression of renal disease: a meta-analysis</article-title>. <source>Kidney Int</source>. <year>2001</year>;<volume>59</volume>(<issue>1</issue>):<fpage>260</fpage>–<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr28-0003319711409391">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papageorgiou</surname>
<given-names>AVG</given-names>
</name>
<name>
<surname>Athanasios</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Elisaf</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dimitri</surname>
<given-names>P.</given-names>
</name>
</person-group> <article-title>Statins and renal function in patients with diabetes mellitus</article-title>. <source>Curr Med Res Opin</source>. <year>2003</year>;<volume>19</volume>(<issue>7</issue>):<fpage>615</fpage>–<lpage>617</lpage>.</citation>
</ref>
<ref id="bibr29-0003319711409391">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Athyros</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Liberopoulos</surname>
<given-names>EN</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study</article-title>. <source>Nephrol Dial Transpl</source>. <year>2007</year>;<volume>22</volume>(<issue>1</issue>):<fpage>118</fpage>–<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr30-0003319711409391">
<label>30</label>
<citation citation-type="journal">
<collab collab-type="author">The FIELD study investigators</collab>. <article-title>Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD) study: randomized controlled trial</article-title>. <source>Lancet</source>. <year>2005</year>;<volume>366</volume>(<issue>9500</issue>):<fpage>1849</fpage>–<lpage>1861</lpage>.</citation>
</ref>
<ref id="bibr31-0003319711409391">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abrass</surname>
<given-names>CK.</given-names>
</name>
</person-group> <article-title>Overview: obesity: what does it have to do with kidney disease?</article-title> <source>J Am Soc Nephrol</source>. <year>2004</year>;<volume>15</volume>(<issue>11</issue>):<fpage>2768</fpage>–<lpage>2772</lpage>.</citation>
</ref>
<ref id="bibr32-0003319711409391">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pataap</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>SP</given-names>
</name>
<etal/>
</person-group>. <article-title>Central obesity is an independent risk factor for albuminuria in nondiabetic south asian subjects</article-title>. <source>Diabetes Care</source>. <year>2007</year>;<volume>30</volume>(<issue>7</issue>):<fpage>1840</fpage>–<lpage>1844</lpage>.</citation>
</ref>
<ref id="bibr33-0003319711409391">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Block</surname>
<given-names>CEM</given-names>
</name>
<name>
<surname>De Leeuw</surname>
<given-names>IH</given-names>
</name>
<name>
<surname>Van Gaal</surname>
<given-names>LF.</given-names>
</name>
</person-group> <article-title>Impact of overweight on chronic microvascular complications in type 1 diabetic patients</article-title>. <source>Diabetes Care</source>. <year>2005</year>;<volume>28</volume>(<issue>7</issue>):<fpage>1649</fpage>–<lpage>1655</lpage>.</citation>
</ref>
<ref id="bibr34-0003319711409391">
<label>34</label>
<citation citation-type="journal">
<collab collab-type="author">UK Prospective Diabetes Study Group</collab>. <article-title>Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38)</article-title>. <source>BMJ</source>. <year>1998</year>;<volume>317</volume>(<issue>7160</issue>):<fpage>703</fpage>–<lpage>713</lpage>.</citation>
</ref>
<ref id="bibr35-0003319711409391">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gross</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>de Azevedo</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Silveiro</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Canani</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Caramori</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Zelmanovitz</surname>
<given-names>T.</given-names>
</name>
</person-group> <article-title>Diabetic nephropathy: diagnosis, prevention, and treatment</article-title>. <source>Diabetes Care</source>. <year>2005</year>;<volume>28</volume>(<issue>1</issue>):<fpage>164</fpage>–<lpage>176</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>